11 results about "Troponin T" patented technology

This invention describes a novel gene regulatory sequence containing the promoter and enhancer sequences of the human cardiac troponin T gene (TNNT2) that selectively induces expression in cardiomyocytes. This novel TNNT2 promoter / enhancer composition can be used to induce adeno-associated virus gene expression, construct cell-type-specific expression vectors, or perform cardiac-specific transgenesis. The use of this novel promoter / enhancer composition is demonstrated by the expression of mAKAP shRNA and a mAKAP-derived anchor-disrupting peptide useful for the treatment of heart failure.

The invention relates to the technical field of biomedicine and cardiovascular disease treatment, and discloses application of an Aralar myocardial overexpression virus in preparation of a medicine for treating heart failure. The related product is a gene therapy preparation containing an effective amount of AAV9-cTnT-Aralar, and can be matched with pharmaceutically acceptable carriers, diluents and other auxiliary materials, and the preparation is an injection type. The preparation method comprises the following steps: firstly, constructing a cardiac troponin T-carrying promoter and an AAV9 carrier of an Aralar coding nucleic acid to form a recombinant adeno-associated virus, and then matching the virus with proper auxiliary materials to prepare the preparation. The product can be used for treating heart failure accompanied with mitochondrial dysfunction, can realize heart targeted delivery and myocardial cell specific overexpression of Aralr, relieves the heart failure course by improving the myocardial cell mitochondrial function and dynamic balance, and is good in preparation stability, convenient in administration and adaptive to clinical application requirements.

To provide an antibody that specifically binds to human cardiac troponin T.SOLUTION: An antibody is provided in which CDRs comprise the following amino acid sequences or a variant thereof that differs in at most one amino acid substitution: In a light chain variable domain a CDR1 comprising a specific amino acid sequence, a CDR2 comprising a specific amino acid sequence, and a CDR3 comprising a specific amino acid sequence, and in a heavy chain variable domain a CDR1 comprising a specific amino acid sequence, a CDR2 comprising a specific amino acid sequence, and a CDR3 comprising a specific amino acid sequence.SELECTED DRAWING: Figure 5

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and / or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SARS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity / mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

A composition comprising at least one peptide derived from the C-terminal segment of troponin T, the at least one peptide optionally fused to at least one cardiac-targeting peptide and / or at least one cell-penetrating peptide, polynucleotides and vectors encoding the composition, and methods of using the composition and vector in a method of treating heart failure, e.g., diastolic heart failure.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.

The myocardial cell population comprises myocardial cells obtained by differentiation of human pluripotent stem cells, and the myocardial cell population has the following characteristics: (1) cardiac troponin T positive cells account for 90% or more; (2) the spontaneous pulsation is 0 to 60 times per minute; and (3) the myocardial cell population is a cell population within 30 days from the start of differentiation. The invention also relates to a pharmaceutical composition which comprises the myocardial cell population and / or myocardial cell spheres obtained by forming the myocardial cell population into spheres, and a pharmaceutically acceptable carrier. A method of preparing the myocardial cell population comprises: (a) expanding human pluripotent stem cells; (b) culturing the expanded human pluripotent stem cells under conditions to differentiate into cardiomyocytes to produce a cell population comprising 60% or more of cardiomyocytes; and (c) removing human pluripotent stem cells and non-myocardial cells from the cell population.

The invention discloses application of a flavonoid compound or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating myocardial injury and / or heart aging. The flavonoid compound has a structure as shown in a formula (I). The flavonoid compound can increase the activity of cardiac muscle cells, inhibit the active oxygen level of the cardiac muscle cells, reduce the aging positive rate of the cardiac muscle cells, relieve neutrophil infiltration and muscle fiber breakage of cardiac muscle tissues and reduce the expression level of brain natriuretic peptide (BNP) and troponin T (cTnT) in serum. (I)

The present invention describes a novel gene regulatory sequence comprising the promoter and enhancer sequences of the human cardiac troponin T gene (TNNT2) that guide selective expression in cardiac muscle cells. The novel TNNT2 promoter / enhancer composition can be used for guiding adeno-associated virus gene expression, or used for constructing a cell type specific expression vector, or used for heart specific transgenosis. Uses of the novel promoter / enhancer compositions are demonstrated by expression of mAKAP shRNA, as well as anchor disrupting peptides derived from mAKAP, useful for the treatment of heart failure.